Product Description
Mechanisms of Action: TNF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India
Approved Indications: None
Known Adverse Events: None
Company: Third Military Medical University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2000034019 | N/A |
Recruiting |
Prostate Cancer |
2024-06-23 |
|
KLKN 14-04-2014 | N/A |
Completed |
Osteoporosis|Bone Diseases, Metabolic |
2016-10-01 |
|
4P-07-3 | P2 |
Completed |
Prostate Cancer |
2014-07-08 |
|
ISOII | N/A |
Completed |
Menopause |
2012-09-01 |